An Easy-to-Use Blue Brush
May Save Your Life

BrochurePrint the InSure® FIT™ Patient Education Pamplet to bring to your physician and Request The Test.

About Colon Cancer

Colon Cancer: America’s Third Most Common Type of Cancer

  • Colorectal cancer is the third most common type of cancer among men and women in the United States.1 The American Cancer Society estimates that about 108,070 new cases of colon cancer (53,760 in men and 54,310 in women) and 40,740 new cases of rectal cancer (23,490 in men and 17,250 in women) will be diagnosed in 2008.
  • In the United States, a man's average lifetime risk of colon cancer is about one in 17. For a woman, the risk is about one in 19.2
  • Medical experts advise that anyone at age 50 or older at average risk should, as one of their screening options, be screened annually with the fecal occult blood test (FOBT) or the newer fecal immunochemical (FIT) for this disease. Talk to your doctor about screening earlier if you believe you are at higher than average risk for colorectal cancer.3


Colorectal Cancer Screening is Important.
Are You a Doubter or a Doer? These Facts Will Turn You Around. 

  • Colorectal cancer screening works! The number of deaths from colorectal cancer has been declining for the past 15 years, likely due in part to increased screening, which allows for earlier detection of cancer and precancerous polyps and earlier treatment. Because of this, there are now about 1 million colorectal cancer survivors in the United States.4
  • If caught earlier (in the localized stage), the relative five-year survival rate for colorectal cancer is higher than 90%, compared with only about 10% in people with advanced disease.

Screening is the most important tool for catching colorectal cancer early.2

Your risk of getting colorectal cancer increases with age. Men and women with a personal or family history of colorectal cancer and/or polyps or a history of inflammatory bowel disease may be at higher risk. Obesity, physical inactivity, heavy alcohol consumption, smoking, and diets high in red or processed meat may also increase the risk of developing colorectal cancer.4

Medical experts recommend, as one of the screening options, annual colorectal cancer screening using FOBT or FIT tests.1,2 There are numerous screening options, including but not limited to:

  • A fecal immunochemical test (FIT) or fecal occult blood test (FOBT) every year; or
  • Flexible sigmoidoscopy every 5 years; or
  • An FIT or FOBT every year plus flexible sigmoidoscopy every 5 years (of these first 3 options, the combination of FIT or FOBT every year plus flexible sigmoidoscopy every 5 years is preferable.); or
  • Double-contrast barium enema every 5 years; or
  • Colonoscopy every 10 years.

In a U.S. clinical study, colorectal cancer deaths were reduced by 33% when annual fecal occult blood tests were performed.5

Underuse of Screening

Colorectal cancer screening remains underused, despite the availability of effective screening tests.6

  • Screening for colorectal cancer lags far behind screening for breast and cervical cancers.
  • As many as 60% of deaths from colorectal cancer could be prevented if everyone age 50 and older were screened regularly.
  • In one study, the InSure® FIT™ test with the more convenient Blue Brush Method had as much as 66% better compliance compared to a leading guaiac-based FOBT screening test.7

References:

  1. Centers for Disease Control and Prevention. Colorectal Cancer: Basic Information:
  2. Mayo Foundation for Medical Education and Research (MFMER)
  3. U.S. Preventive Services Task Force. Screening for Colorectal Cancer: Recommendations and Rationale. July 2002. Agency for Healthcare Research and Quality, Rockville, MD.
  4. American Cancer Society. Colorectal Cancer: Early Detection. Accessed February 4, 2008.
  5. Mandel, J.S., et al.: “Reducing mortality from colorectal cancer by screening for fecal occult blood”. N.Eng.J.Med 328:1365-1371, 1993
  6. Centers for Disease Control and Prevention. Colorectal Cancer: Screening Rates.
  7. Cole SR, Young GP, Esterman A, Cadd A, Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen 2003;10:117-122.